Collegium Pharmaceutical, Inc. (COLL) Shares Bought by J. Goldman & Co LP

J. Goldman & Co LP increased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 188.3% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 224,850 shares of the specialty pharmaceutical company’s stock after buying an additional 146,850 shares during the period. J. Goldman & Co LP owned approximately 0.96% of Collegium Pharmaceutical worth $3,501,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in COLL. Rock Springs Capital Management LP boosted its position in shares of Collegium Pharmaceutical by 27.2% in the third quarter. Rock Springs Capital Management LP now owns 1,545,000 shares of the specialty pharmaceutical company’s stock valued at $29,757,000 after buying an additional 330,000 shares during the last quarter. FMR LLC boosted its position in shares of Collegium Pharmaceutical by 20.2% in the fourth quarter. FMR LLC now owns 915,673 shares of the specialty pharmaceutical company’s stock valued at $14,257,000 after buying an additional 153,600 shares during the last quarter. Sectoral Asset Management Inc boosted its position in shares of Collegium Pharmaceutical by 139.8% in the third quarter. Sectoral Asset Management Inc now owns 705,845 shares of the specialty pharmaceutical company’s stock valued at $13,595,000 after buying an additional 411,445 shares during the last quarter. Cadian Capital Management LP acquired a new position in shares of Collegium Pharmaceutical during the third quarter valued at $9,248,000. Finally, State Street Corp boosted its position in shares of Collegium Pharmaceutical by 46.1% in the fourth quarter. State Street Corp now owns 289,219 shares of the specialty pharmaceutical company’s stock valued at $4,530,000 after buying an additional 91,287 shares during the last quarter. 56.60% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) traded up 1.41% during midday trading on Tuesday, reaching $15.15. 1,409,613 shares of the company’s stock traded hands. The firm’s 50-day moving average is $15.74 and its 200 day moving average is $14.80. Collegium Pharmaceutical, Inc. has a 52-week low of $8.24 and a 52-week high of $21.45. The firm’s market cap is $355.42 million.

“Collegium Pharmaceutical, Inc. (COLL) Shares Bought by J. Goldman & Co LP” was originally posted by sleekmoney and is the property of of sleekmoney. If you are viewing this story on another domain, it was stolen and republished in violation of US and international copyright legislation. The legal version of this story can be viewed at http://sleekmoney.com/collegium-pharmaceutical-inc-coll-shares-bought-by-j-goldman-co-lp/1661019.html.

Several equities analysts recently weighed in on the stock. Zacks Investment Research cut shares of Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Monday, October 24th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $24.00 price target (down previously from $27.00) on shares of Collegium Pharmaceutical in a research report on Friday, November 11th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Collegium Pharmaceutical currently has an average rating of “Buy” and an average target price of $25.57.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza), is an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication.

5 Day Chart for NASDAQ:COLL

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/collegium-pharmaceutical-inc-coll-shares-bought-by-j-goldman-co-lp/1661019.html

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *